Detection of a novel RYR1 mutation in four malignant hyperthermia pedigrees

Katherine E. Keating, Kathleen A. Quane, Bernadette M. Manning, Mary Lehane, Edmund Hartung, Kathrin Censier, Albert Urvyler, Monika Klausnitzer, Clemens R. Müller, James J. Heffron and Tommie V. McCarthy*

Department of Biochemistry and *Department of Anaesthesia, University College, Cork, Ireland, †Institute for Anaesthesiology, Josef Schneider Str 2, D-97080 Würzburg, Germany. ‡Department of Anaesthesia and Research, University Hospital, CH-4031 Basel, Switzerland and §Department of Human Genetics, University of Würzburg Biozentrum, Am Hubland, D-97074 Würzburg, Germany

Received June 20, 1994; Revised and Accepted July 29, 1994

Malignant hyperthermia (MH) is a potentially fatal autosomal dominant disorder of skeletal muscle and is triggered in susceptible people by all commonly used inhalational anaesthetics and depolarizing muscle relaxants. To date, six mutations in the skeletal muscle ryanodine receptor gene (RYR1) have been identified in malignant hyperthermia susceptible (MHS) and central core disease (CCD) cases. Using SSCP analysis, we have screened the RYR1 gene in affected individuals for novel MHS mutations and have identified a G to A transition mutation which results in the replacement of a conserved Gly at position 2433 with an Arg. The Gly2433Arg mutation was present in four of 104 unrelated MHS individuals investigated and was not detected in a normal population sample. This mutation is adjacent to the previously identified Arg2434His mutation reported in a CCD/MH family and indicates that there may be a second region in the RYR1 gene where MHS/CCD mutations cluster.

INTRODUCTION

Malignant hyperthermia (MH) is an autosomal dominant disorder of skeletal muscle and is one of the main causes of death due to anaesthesia. In susceptible people, an MH episode can be triggered by all commonly used inhalational anaesthetics such as halothane and by depolarizing muscle relaxants such as succinylcholine. The clinical features of the myopathy are hyperthermia, accelerated muscle metabolism, contractures, metabolic acidosis and tachycardia (reviewed in 1).

Susceptibility to MH (MHS) is predicted by observing the magnitude of contractures induced in strips of muscle tissue in vitro by caffeine alone and halothane alone (2,3). This test is called the in vitro contracture test (IVCT). Patients who exhibit a normal response are diagnosed as MH normal (MHN) while those with an abnormal response to both caffeine and halothane are diagnosed as MH susceptible (MHS). Patients exhibiting an abnormal response to caffeine alone or halothane alone are diagnosed as MH equivocal (MHE(c) and MHE(h) respectively) (3).

Molecular genetic studies have shown that the MHS locus maps to the RYR1 region of human chromosome 19q in many cases (4,5) and to date, six RYR1 mutations have been reported in MHS and central core disease (CCD) pedigrees. CCD is a rare inherited myopathy closely associated with MHS (6,7).

The first reported RYR1 mutation resulted in an Arg to Cys substitution at position 614 and has been found in 3–5% of human MH families investigated (8). This mutation was also shown to be present in all cases of swine affected with MH (9). Recently, we reported a Gly to Arg substitution at position 341 which accounts for approximately 10% of MHS cases investigated (10) and an Arg163Cys mutation (11) which accounts for 2–3% of MHS cases and a CCD case. The mutations Gly248Arg, Ile403Met and Arg2434His have also been reported in the RYR1 gene in three independent MHS and/or CCD pedigrees and appear to be private mutations (11–13).

Genetic heterogeneity has been reported in MH (14,15) and a second MHS locus has been tentatively localized to the q11.2–q24 region of chromosome 17 in North American pedigrees (16). Recent linkage studies in European MHS pedigrees support the existence of genetic heterogeneity but have excluded the possibility of a second MHS locus mapping to 17q11.2–q24 (17,18).

In an effort to identify new mutations in the RYR1 gene causing MH we have undertaken the systematic screening of the 15.5 kb RYR1 gene in unrelated MHS individuals for mutations. We describe here the identification of a novel Gly2433Arg mutation which we detected in four unrelated MHS pedigrees.

RESULTS

SSCP analysis of the RYR1 gene in MH

For mutation analysis, cDNA was synthesized from total RNA isolated from skeletal muscle biopsy samples from 21 unrelated MHS patients. The previously reported MHS mutations were not detected in these samples (data not shown). Screening for single base-pair changes in polymerase chain reaction (PCR) amplified RYR1 segments from the MHS patients was performed using the single-stranded conformation polymorphism (SSCP) method (19). PCR primers were designed so that the 15.5 kb coding sequence of the RYR1 gene (20) could be amplified in short (250–450 bp) overlapping segments. Aberrant SSCP patterns were detected in different areas of the RYR1 gene in 21 MHS patients. The majority of the SSCP's detected in these segments reflected commonly occurring polymorphisms (12). However, of the SSCP's detected, an aberrant pattern was present in RYR1 segment 6995–7393 (Figure 1) in patient III-3 of pedigree A (Figure 2) and direct sequencing showed the presence of the single...
base substitution G7297A which results in the replacement of a Gly with an Arg at position 2433 (Figure 3). The complete RYR1 gene in patient III-3 was investigated by SSCP analysis under three different electrophoretic conditions alongside control MHN samples and MHS samples known to bear the previously characterized Arg614Cys (21) or Gly341Arg (10) mutations. In addition to the SSCP in segment 6995–7393, SSCPs were detected in nine different segments of the RYR1 gene from patient III-3. The nine SSCPs were considered innocuous polymorphisms as they were present in some of the control samples and/or were shown to be due to previously reported polymorphisms by restriction enzyme analysis (12).

As the G7297A mutation creates AlwNI and Ddel restriction sites, either of these enzymes can be employed to check for the presence of the mutations in amplified RYR1 segments. In order to check for the presence of the G7297A missense mutation in the multi-exon RYR1 gene (8) in genomic DNA samples, it was necessary to design PCR primers that would allow amplification of the mutated region from genomic DNA. Using the primers 7270 and 7301 (see Materials and Methods), it was possible to amplify a 55 bp genomic fragment encompassing the G7297A mutation. The amplified fragment was the same size as anticipated from the cDNA sequence and the presence of the mutation was verified by selective cleavage with the restriction enzyme AlwNI (Figure 4).

To establish whether the Gly2433Arg missense mutation was present in the normal population, 200 normal chromosomes were examined for the presence of the mutation. None displayed the candidate mutation. In order to determine whether this mutation was present in the RYR1 gene of other MHS pedigrees and/or CCD pedigrees, 83 additional unrelated MHS and four unrelated CCD patients were investigated for the presence of the mutation. The mutation was detected in one Irish and two German MHS patients (individuals HI-8, IV-1 and IH-1 of pedigrees B, C and D, respectively).

Segregation analysis of the Gly2433Arg mutation was performed in the families of individuals displaying the mutation and showed that the mutation co-segregated with the MHS phenotype in each family with the exception of one individual, namely individual III-5 of pedigree A (Figure 2).

DISCUSSION

In an effort to identify new mutations in the RYR1 gene causing MHS, we have investigated the RYR1 gene in unrelated MHS patients for the presence of new mutations by the SSCP method and have detected a novel Gly2433Arg mutation in four of 104 unrelated Caucasian MHS patients. The Gly2433Arg mutation segregates with MHS in the pedigrees investigated with the exception of individual III-5 of pedigree A. The MHS diagnosis of the individuals in family A by the IVCT was performed in 1982, prior to the introduction of the standardized IVCT protocol (3). At this time, a patient was diagnosed as MHS if muscle biopsy strips produced a sustained increase of 0.2 g baseline tension at a caffeine concentration of 2 mM or less. The result of the contracture test on individual HI-5 was 0.64 g at 2 mM caffeine and therefore, individual EH-5 was diagnosed as MHS. Since the introduction of the standardized IVCT protocol, MHS diagnosis requires that the patient exhibits a positive response.
addition, examination of the RYR1 genes sequenced to date (9,20) strongly in favour of this mutation being causative of MHS. In the absence of the mutation in 200 normal chromosomes tested argues that an abnormal IVCT response is present in family A. However, it is possible that a second mutation causing MHS or contributing to the MHS phenotype in the pedigrees investigated and the absence of the mutation in individual III-5 is that this individual has recorded a false positive reaction in the IVCT. In support of this notion, it has been reported that the North American IVCT protocol (which is largely similar to the European protocol) achieves a sensitivity of 100% in MHS detection. However, to achieve this sensitivity, the specificity of the test is compromised to 78% (22). Therefore, it is reasonable to assume that false positive diagnoses also exist using the European protocol especially before standardization in 1984. Furthermore, we have recently shown (10) that responses of up to 0.9 g tension occurred in Gly341Arg negative MHE(c) individuals within pedigrees in which the Gly341Arg mutation was segregating precisely with the MHS phenotype (10). It is possible that a second mutation causing MHS or contributing to an abnormal IVCT response is present in family A. However, the tight association between the Gly2433Arg mutation and the MHS phenotype in the pedigrees investigated and the absence of the mutation in 200 normal chromosomes tested argues strongly in favour of this mutation being causative of MHS. In addition, examination of the RYR1 genes sequenced to date (9,20) and related cardiac (RYR2) (23) and brain (RYR3) (24) genes indicates that Gly2433 is a functionally important amino acid in the RYR proteins since it is conserved across species (Figure 5). To obtain conclusive proof that this is a causative mutation, it will be necessary to investigate the effect of the Gly2433Arg mutation on the RYR1 channel activity and/or determine its effects in an animal model system.

Family B is unusual in that three of the four siblings were diagnosed as MHE(h). None of these individuals had the Gly2433Arg mutation. Examination of their contracture records shows that they all exhibited a marginal response to halothane which suggests that these patients may be normal from both a genetic and clinical viewpoint. However, since about 12% of probands are diagnosed as MHE in the IVCT (25) it is essential to classify all MHE individuals (including those in which an obvious MHS mutation is not segregating) as MHS until the relationship between the MHS and MHE phenotypes becomes much clearer.

The mutation reported here has diagnostic potential. However, as misdiagnosis could be fatal and as the reason for the apparent occurrence of the MHS false positive and MHE phenotypes is currently unclear, we strongly advocate corroboration of genetic diagnosis with the IVCT.

The detection of the Gly2433Arg mutation brings to seven the total number of RYR1 mutations reported to date in MHS/CCD pedigrees. Five of the previously reported MHS/CCD mutations cluster in the amino terminal region of the RYR1 protein whereas the Gly2433Arg mutation is positioned adjacent to the previously identified Arg2434His CCD mutation. Interestingly, none of the patients with the Gly2433Arg mutation had clinical signs of CCD. Only family B has been investigated histologically and none of the MHS individuals in this family exhibited central cores. This indicates that the Gly2433Arg mutation is associated with a milder phenotype than the Arg2434His mutation. The location of a second mutation close to the Arg2434His CCD mutation indicates that there may be a second region in the RYR1 gene where MHS/CCD mutations cluster. The Gly2433Arg and the Arg2434His mutations occur in a domain of the RYR1 protein thought to be modulated by ATP, phosphorylation and calmodulin binding (26). It will be interesting to determine if these mutations alter channel regulation with respect to these modulators.

**MATERIALS AND METHODS**

Genomic DNA was extracted from peripheral blood as described (27). Total RNA was extracted from 100 mg muscle biopsy samples by guanidinium thiocyanate extraction (28). First strand cDNA synthesis and PCR amplification of RYR1 gene segments was carried out using overlapping primers designed from the published human RYR1 sequence (20), as previously described (10). Nondenaturing gel electrophoresis for SSCP detection and direct sequencing of PCR products was performed as previously described (10).

**Segregation studies**

A 55 bp fragment spanning the G7297A mutation of the RYR1 gene was amplified from genomic DNA using PCR. The reactions were carried out in a total volume of 10 μl, with 100 ng of genomic DNA, 20 ng of each primer T720 (5’-TTCTACTGCCGCTTTGATCGACCTG-3’) and 7301 (5’-TTAGATCTCCTCTGGTGACGAC-3’), 0.2 mM of each dNTP, 50 mM KCl, 10 mM Tris-HCL, pH 9.0 at 25°C, 0.1% Triton X-100, 1.5 mM MgCl2 and 0.5 U of Taq polymerase (Perkin Elmer) and 2 μCi of α-32P dCTP (3000 Ci/mmol). A thermal profile of 94°C
for 5 min followed by 94°C for 1 min, 51°C for 1 min and 72°C for 1 min for 30 cycles and then 72°C for 10 min was performed. A 1 µl aliquot of the amplified 55 bp genomic fragment was then cleaved with DdeNI in a reaction volume of 10 µl. The G7297A mutation results in the creation of the DdeNI site, producing 27 and 28 bp digestion fragments. Digestion products were resolved by electrophoresis through 20% polyacrylamide gels and visualized by autoradiography.

Patients
For the investigations reported here, muscle samples were obtained from 21 MHS patients and five MHN through the Cork, Basel and Wurzburg MH testing centres. The patients in pedigree A were tested for MH susceptibility prior to 1984 using an IVCT caffeine protocol similar to the standardized European Malignant Hyperthermia Group protocol (3) established in 1984. All other patients were investigated post-1984 using the standardized protocol. The probands in each pedigree are: pedigree A: m-14; pedigree B: m-3; pedigree C: IV-1; and pedigree D: m-1. Each proband suffered an MH episode during anaesthesia and recovered.

ACKNOWLEDGMENTS
This work was supported by grants from the Irish Health Research Board, the Wellcome Trust and the Deutsche Forschungsgemeinschaft (Mu 518/6-2).

REFERENCES